Universal antifungal therapy is not needed in persistent febrile neutropenia: A tailored diagnostic and therapeutic approach

Haematologica

Volumn 97, Issue 3, 2012, Pages 464-471

  Aguilar Guisado, Manuela ^a   Martín Peña, Almudena ^a   Espigado, Ildefonso ^a,b   de Pipaon, Maite Ruiz Pérez ^a   Falantes, José ^a,b   de la Cruz, Fátima ^a,b   Cisneros, José M ^a  

^a HOSPITAL UNIVERSITARIO VIRGEN DEL ROCÍO   (Spain)

^b Hematology Service   (Spain)

Author keywords

Empirical antifugal therapy; Invasive fungal infection; Persistent febrile neutropenia; Selective antifugal therapy

Indexed keywords

AMPHOTERICIN; ANTIFUNGAL AGENT; CASPOFUNGIN; COTRIMOXAZOLE; FLUCONAZOLE; LEVOFLOXACIN; POSACONAZOLE;

ABDOMINAL INFECTION; ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL EFFECTIVENESS; DIAGNOSTIC ACCURACY; DISEASE DURATION; FEBRILE NEUTROPENIA; FEMALE; HIGH RISK PATIENT; HUMAN; INCIDENCE; INFECTION RISK; LUNG INFILTRATE; MAJOR CLINICAL STUDY; MALE; MYCOSIS; PREDICTIVE VALUE; PROSPECTIVE STUDY; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; SURVIVAL RATE; VALIDITY;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; FEVER; HUMANS; MIDDLE AGED; MYCOSES; NEUTROPENIA; PROSPECTIVE STUDIES; SENSITIVITY AND SPECIFICITY; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84857702567     PISSN: 03906078     EISSN: 15928721     Source Type: Journal    
DOI: 10.3324/haematol.2011.049999     Document Type: Article

References (29)

1. Pagano L, Caira M, Valentini CG, Posteraro B, Fianchi L. Current therapeutic approaches to fungal infections in immunocompromised hematological patients. Blood Rev. 2010;24(2):51-61.
2. Neofytos D, Horn D, Anaissie E, Steinbach W, Olyaei A, Fishman J, et al. Epidemiology and outcome of invasive fungal infection in adult hematopoietic stem cell transplant recipients: analysis of Multicenter Prospective Antifungal Therapy (PATH) Alliance registry. Clin Infect Dis. 2009;48 (3):265-73.
3. Pagano L, Girmenia C, Mele L, Ricci P, Tosti ME, Nosari A, et al. Infections caused by filamentous fungi in patients with hematologic malignancies. A report of 391 cases by GIMEMA Infection Program. Haematologica. 2001;86(8):862-70.
4. Pagano L, Caira M, Candoni A, Offidani M, Fianchi L, Martino B, et al. The epidemiology of fungal infections in patients with hematologic malignancies: the SEIFEM-2004 study. Haematologica. 2006;91(8): 1068-75.
5. Hughes WT, Armstrong D, Bodey GP, Bow EJ, Brown AE, Calandra T, et al. 2002 guidelines for the use of antimicrobial agents in neutropenic patients with cancer. Clin Infect Dis. 2002;34(6):730-51.
6. Pizzo PA, Robichaud KJ, Gill FA, Witebsky FG. Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia. Am J Med. 1982; 72(1):101-11.
7. Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340(10): 764-71.
8. Walsh TJ, Pappas P, Winston DJ, Lazarus HM, Petersen F, Raffalli J, et al. Voriconazole compared with liposomal amphotericin B for empirical antifungal therapy in patients with neutropenia and persistent fever. N Engl J Med. 2002;346(4):225-34.
9. Walsh TJ, Teppler H, Donowitz GR, Maertens JA, Baden LR, Dmoszynska A, et al. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N Engl J Med. 2004;351(14):1391-402.
10. Aguilar-Guisado M, Espigado I, Cordero E, Noguer M, Parody R, Pachon J, et al. Empirical antifungal therapy in selected patients with persistent febrile neutropenia. Bone Marrow Transplant. 2010;45(1):159-64.
11. Cherif H, Kalin M, Bjorkholm M. Antifungal therapy in patients with hematological malignancies: how to avoid overtreatment? Eur J Haematol. 2006;77(4): 288-92.
12. Cisneros JM, Espigado I, Rivero A, Lozano DL, Parra J, Collado AR, et al. Empirical antifungal therapy in selected patients with persistent fever and neutropenia. Enferm Infecc Microbiol Clin. 2005;23(10):609-14.
13. Cordonnier C, Pautas C, Maury S, Vekhoff A, Farhat H, Suarez F, et al. Empirical versus preemptive antifungal therapy for highrisk, febrile, neutropenic patients: a randomized, controlled trial. Clin Infect Dis. 2009;48(8):1042-51.
14. Maertens J, Theunissen K, Verhoef G, Verschakelen J, Lagrou K, Verbeken E, et al. Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study. Clin Infect Dis. 2005;41(9):1242-50.
15. Ascioglu S, Rex JH, de Pauw B, Bennett JE, Bille J, Crokaert F, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis. 2002;34(1):7-14.
16. Boogaerts M, Winston DJ, Bow EJ, Garber G, Reboli AC, Schwarer AP, et al. Intravenous and oral itraconazole versus intravenous amphotericin B deoxycholate as empirical antifungal therapy for persistent fever in neutropenic patients with cancer who are receiving broad-spectrum antibacterial therapy. A randomized, controlled trial. Ann Intern Med. 2001;135(6):412-22.
17. Winston DJ, Hathorn JW, Schuster MG, Schiller GJ, Territo MC. A multicenter, randomized trial of fluconazole versus amphotericin B for empiric antifungal therapy of febrile neutropenic patients with cancer. Am J Med. 2000;108(4):282-9.
18. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, et al. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. Crit Care Med. 2004;32(3):858-73.
19. Walsh TJ, Anaissie EJ, Denning DW, Herbrecht R, Kontoyiannis DP, Marr KA, et al. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin Infect Dis. 2008;46(3):327-60.
20. Dignan FL, Evans SO, Ethell ME, Shaw BE, Davies FE, Dearden CE, et al. An early CTdiagnosis-based treatment strategy for invasive fungal infection in allogeneic transplant recipients using caspofungin first line: an effective strategy with low mortality. Bone Marrow Transplant. 2009;44(1):51-6.
21. Girmenia C, Micozzi A, Gentile G, Santilli S, Arleo E, Cardarelli L, et al. Clinically driven diagnostic antifungal approach in neutropenic patients: a prospective feasibility study. J Clin Oncol. 2010;28(4):667-74.
22. Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(4):503-35.
23. Herbrecht R, Denning DW, Patterson TF, Bennett JE, Greene RE, Oestmann JW, et al. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis. N Engl J Med. 2002;347(6):408-15.
24. Kubiak DW, Bryar JM, McDonnell AM, Delgado-Flores JO, Mui E, Baden LR, et al. Evaluation of caspofungin or micafungin as empiric antifungal therapy in adult patients with persistent febrile neutropenia: a retrospective, observational, sequential cohort analysis. Clin Ther. 2010;32(4):637-48.
25. Lafaurie M, Lapalu J, Raffoux E, Breton B, Lacroix C, Socie G, et al. High rate of breakthrough invasive aspergillosis among patients receiving caspofungin for persistent fever and neutropenia. Clin Microbiol Infect. 2010;16(8):1191-6.
26. Cuenca-Estrella M, Meije Y, Diaz-Pedroche C, Gomez-Lopez A, Buitrago MJ, Bernal-Martinez L, et al. Value of serial quantification of fungal DNA by a real-time PCRbased technique for early diagnosis of invasive Aspergillosis in patients with febrile neutropenia. J Clin Microbiol. 2009;47(2): 379-84.
27. Donnelly JP. Polymerase chain reaction for diagnosing invasive aspergillosis: getting closer but still a way to go. Clin Infect Dis. 2006;42(4):487-9.
28. Loeffler J, Ok M, Morton OC, Mezger M, Einsele H. Genetic polymorphisms in the cytokine and chemokine system: their possible importance in allogeneic stem cell transplantation. Curr Top Microbiol Immunol. 2010;341:83-96.
29. Senn L, Robinson JO, Schmidt S, Knaup M, Asahi N, Satomura S, et al. 1,3-Beta-Dglucan antigenemia for early diagnosis of invasive fungal infections in neutropenic patients with acute leukemia. Clin Infect Dis. 2008;46(6):878-85.